For 25 dollars up stocks
$INTC
$TEVA
$GILD
$MGM
$GM
$BP
$ALXN
$ACIA
$TPX - pinch
$RH - pinch coming
$PX
$ISK
$WWAV
Nice bottom
RT @ChrisLacoursier: @steveubl @PhRMA $NWBO trial overwhelmingly extending life in #braincancer $BMY $JUNO $GILD $CELG can not do this http…
RT @lancejepsen: Gilead Sciences Candle Over Candle Reversal On Carl Icahn Rumors $GILD #stockmarket #stocktrading https://t.co/R0p6TpXRk2…
#WallStreet $GILD good HIV news, last call to board rocketship https://t.co/eWUqrr3Ta5 https://t.co/37rkiL8lSB https://t.co/LPB3MAxLXA
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @SeekingAlpha: Biotech Forum Daily Digest: Closing Out A '10-Bagger'. Taking A Look At Pieris Pharmaceuticals https://t.co/D7AOFmhPjI $A…
9 Top Pharmaceutical Stocks to Buy for the Dividends https://t.co/02eBQdShqS $ABBV $GSK $TEVA $SNY $AZN $PFE $GILD… https://t.co/bi86sViCaW
9 Top Pharmaceutical Stocks to Buy for the Dividends https://t.co/uK9QQ3C8wk $ABBV $GSK $TEVA $SNY $AZN $PFE $GILD… https://t.co/pmibcBZEDc
Biotech Forum Daily Digest: Closing Out A '10-Bagger'. Taking A Look At Pieris Pharmaceuticals https://t.co/8MaDhXor8E $AGN $GILD $SAGE
Biotech Forum Daily Digest: Closing Out A '10-Bagger'. Taking A Look At Pieris Pharmaceuticals https://t.co/D7AOFmhPjI $AGN $GILD $SAGE
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
@adamfeuerstein @TheStreet if positive no need for inhibitor/retrovirals like $GILD drug
Is Gilead Sciences Getting Ready for a Massive Acquisition? @themotleyfool #stocks $VRTX, $GILD, $INCY, $KITE https://t.co/W4HFNMchN5
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @Sandman7591: some nice news for $GILD .... at this price I wouldn't bet against these guys...... https://t.co/CTH0JMWvHs
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
@yusschr @NotaBubble @7wtc Heavy call buying $GILD leaps but massive dumping of stock in large chunks despite "Activist" story - fake news
@adamfeuerstein @matthewherper @TheStreet $GILD: Infectious Disease Today, Infectious Disease Tomorrow, Infectious Disease Forever?
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @JohnCendpts: GSK details PhIII success, preps global rollout for HIV combo as Gilead launches a counterattack
$GSK v. $GILD
https://t.c…
Gilead Sciences Candle Over Candle Reversal On Carl Icahn Rumors $GILD #stockmarket #stocktrading… https://t.co/iDTEbn4DxA
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
@SaltLassi How about going with $IBB rather than individual names? $BIIB $REGN and $GILD also setting up well
RT @daytradingradio: Nice move in $GILD after hours $CIEN is our Best bet for the week but $GILD could take over after $CIEN hits target to…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
$GILD another gap fill play, catch up to 10ema https://t.co/E3kQ7TgJw4
RT @daytradingradio: Nice move in $GILD after hours $CIEN is our Best bet for the week but $GILD could take over after $CIEN hits target to…
RT @OpenOutcrier: RECAP 2/13 Chatter:
$GILD + Icahn
$TEVA + Generics Unit Sale
$MBLY + Volkswagon P-ship
$PLKI + $QSR
RT @osok762: $GILD go ahead and pull the trigger $SGMO https://t.co/wsR3hFC6Ky
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
$GILD go ahead and pull the trigger $SGMO https://t.co/wsR3hFC6Ky
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
Nice move in $GILD after hours $CIEN is our Best bet for the week but $GILD could take over after $CIEN hits target… https://t.co/Pl4UEphuFJ
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
$GSK details PhIII success, preps global rollout for #HIV combo as $GILD launches counterattack https://t.co/296Bl0F8I9 #biotech
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
Better Buy: Illumina or Gilead Sciences? @themotleyfool #stocks $ILMN, $GILD https://t.co/l59bF53dwk
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @OptionsHawk: $GILD Feb IV ramping w/ 3K Feb $66 calls active
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
$GILD and 'Good News' Make A Rare, Joint Appearance at HIV Conference —> https://t.co/tACjFJMNGy
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @adamfeuerstein: @Jessecdghi @CramersShirt I don’t think $GILD is a good candidate for an activist shareholder campaign. What would Icah…
RT @adamfeuerstein: @Jessecdghi @CramersShirt I don’t think $GILD is a good candidate for an activist shareholder campaign. What would Icah…
Million dollar #put #options today need some attention: $PCLN, $TSLA, $NTES, $CMCSA, $GILD https://t.co/tLgmxGwoU6 #iTunes
RT @jsamsoondar: This is great for patients:
$GSK & $GILD trying to outdo each other to see which treatment is better
https://t.co/34EYzDB…
RT @adamfeuerstein: $GILD press release with bictegravir ph2 data coming tonight, after CROI media briefing ends.
@Jessecdghi @CramersShirt I don’t think $GILD is a good candidate for an activist shareholder cam @adamfeuerstein https://t.co/ZjKWoPawMQ
RT @adamfeuerstein: @Jessecdghi @CramersShirt I don’t think $GILD is a good candidate for an activist shareholder campaign. What would Icah…
RT @OptionsMike: $GILD in play tomorrow. https://t.co/3YXOQzSpr4
RT @Sandman7591: some nice news for $GILD .... at this price I wouldn't bet against these guys...... https://t.co/CTH0JMWvHs
RT @CarolineYLChen: $GILD ph 2 trial in HIV with bictegravir - 97% patients had undetectable levels at 24 and 48 weeks. (1/2)
This is great for patients:
$GSK & $GILD trying to outdo each other to see which treatment is better
https://t.co/34EYzDB6jg
RT @CarolineYLChen: Title of Piper report on $GILD HIV top-line: "THAT's What We're Talking 'Bout"
My story on @TheTerminal shortly.
RT @troutbro04: $GILD P2 HIV data better than $GSK looks like we see $75 sooner than we see $55
RT @Toad: $GILD - nice HIV data. Bought shares after hours $68.10 https://t.co/AzZ9yDEozL
RT @brianfires: Sufficient Integrity for a CEO of a Drug Company? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK $GILD $TEVA…
@Jessecdghi @CramersShirt I don’t think $GILD is a good candidate for an activist shareholder campaign. What would Icahn change?
#GileadSciences Gilead Presents New Phase 2 Data on Bictegravir, an Investigational Integra... Read more: https://t.co/NckRspFaUo $GILD
#GileadSciences BRIEF-Gilead presents new phase 2 data on Bictegravir. Read more: https://t.co/fTNbrvulZR $GILD
#GileadSciences Gilead Announces Findings from New Preclinical Study Evaluating Novel Class... Read more: https://t.co/7bfUNyIjp2 $GILD
#GileadSciences BRIEF-Gilead announces findings from new preclinical study evaluating novel... Read more: https://t.co/P2X7ZMAXDC $GILD
RT @techwhitepapers: $GILD CEO says "It makes it challenging for us to grow without an acquisition," https://t.co/wuhdZ4lG7g
RT @Biotech2050: $CELG market cap now > $GILD
So @Celgene can now consider buying out @GileadSciences & using cash generation to pay off bu…
#GileadSciences Gilead Announces Findings from New Preclinical Study Evaluating Novel Class... Read more: https://t.co/wdFoo52zQq $GILD
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @adamfeuerstein: $GILD - detailed presentation of bictegravir data tomorrow, but these top-line results, numerically superior to doluteg…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
Name Change? How About Performance Net Income? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK $GILD… https://t.co/h51W1ARoEa
Performance Net Income? Really? Miss The Mark? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK $GILD… https://t.co/551vKnBBYK
Botox-The Drug that Treats Everything! Everything? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK… https://t.co/1NI4QSTsyC
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
How About " I was told to by the SEC" ? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK $GILD $TEVA $SRPT $PRGO $JPM
2Sufficient Integrity for a CEO of a Drug Company? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK… https://t.co/R8Cg8b1Z2A
Sufficient Integrity for a CEO of a Drug Company? $VRX $AGN $MYL $MRK $JNJ $SNY $PRGO $IEP $HLF $SPY $SPX $BRK… https://t.co/Mae2OJ7w9M
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @CarolineYLChen: Title of Piper report on $GILD HIV top-line: "THAT's What We're Talking 'Bout"
My story on @TheTerminal shortly.
RT @troutbro04: $GILD P2 HIV data better than $GSK looks like we see $75 sooner than we see $55
RT @Toad: $GILD - nice HIV data. Bought shares after hours $68.10 https://t.co/AzZ9yDEozL
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
@adamfeuerstein Something good from $GILD. That is a big surprise. Got used in going down day after day
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
$GILD - nice HIV data. Bought shares after hours $68.10 https://t.co/AzZ9yDEozL
RT @CarolineYLChen: Title of Piper report on $GILD HIV top-line: "THAT's What We're Talking 'Bout"
My story on @TheTerminal shortly.
$GILD P2 HIV data better than $GSK looks like we see $75 sooner than we see $55
Title of Piper report on $GILD HIV top-line: "THAT's What We're Talking 'Bout"
My story on @TheTerminal shortly.
Today's $XBI $IBB dichotomy mainly $REGN and $GILD helping $IBB, $NBIX, $EXEL, $CLVS hurting $XBI.
RT @ChrisLacoursier: @steveubl @PhRMA $NWBO trial overwhelmingly extending life in #braincancer $BMY $JUNO $GILD $CELG can not do this http…
$GILD $67.65 Bullish reversal tweezer bottom followed by gap up. Is this stock finally turning around? https://t.co/vwKketXLC6
RT @OptionsHawk: $GILD Feb IV ramping w/ 3K Feb $66 calls active
Citi:" $GILD raises the bar in HIV with Bic-TAF, again. Could ease competitive pressure; Bic-TAF data could look even better vs. Triumeq..."
Gilead Sciences, Inc. $GILD Cut to Neutral at Citigroup Inc. https://t.co/u7sKLdQyoj
Gilead Sciences, Inc. $GILD Earns Hold Rating from Needham & Company LLC https://t.co/b2ooSxBOxb
Gilead Sciences, Inc. $GILD Earns Hold Rating from Needham & Company LLC https://t.co/I1m6hjV9gy
#CROI2017 Jefferies: Tonight, $GILD 's Bic "Pen" Mightier Than $GSK 's SWORD Detailed SWORD data confirm (cont) https://t.co/0i1fFPYDEU
Connor Bruggeman SchoolTrader made $300,000 and he is only 17! https://t.co/KkksP3bdM5 $DIS $ALXN $NOAH $GILD $QUNR
#CROI2017 UBS: Gilead's $GILD GS-9883 a credible risk to $GSK 's HIV franchise following PhII da @_B_I_O_T_E_C_H_ https://t.co/cvt0RPe8tf
#CROI2017 UBS: Gilead's $GILD GS-9883 a credible risk to $GSK 's HIV franchise following PhII data In our (cont) https://t.co/7QvViU344m
$GILD #CROI2017 Bictegravir tops dolutegravir in phase 2; ViiV doublet non-inferior to CAR We think (cont) https://t.co/rUMdD0TvlY
RT @osok762: $GILD go ahead and pull the trigger $SGMO https://t.co/wsR3hFC6Ky
Is Gilead Sciences Getting Ready for a Massive Acquisition? @themotleyfool #stocks $VRTX, $GILD, $INCY, $KITE https://t.co/49SlGMTC0R
MS $GSK 1st Take: growing competition in HIV #CROI2017 Competitive HIV update from $GILD Gilead suggests a (cont) https://t.co/qqDkrxF9dJ
RT @JohnCendpts: GSK details PhIII success, preps global rollout for HIV combo as Gilead launches a counterattack
$GSK v. $GILD
https://t.c…
RT @TomSilver39: Citi:" $GILD raises the bar in HIV with Bic-TAF, again. Could ease competitive pressure; Bic-TAF data could look even bett…
RT @lancejepsen: Gilead Sciences Candle Over Candle Reversal On Carl Icahn Rumors $GILD #stockmarket #stocktrading https://t.co/R0p6TpXRk2…
Positive Phase II virologic suppression data for F/TAF/BIC (97% at 24w). Will help $GILD recoup #HIV share lost to Triumeq and Tivicay #CROI
RT @sfef84: $GILD Icahn chatter
$GILD *Hearing Carl Icahn Has Taken Stake In Gilead
2/14/17, 4:25 AM
RT @investpro2000: Pharma M&A In 2017: The Most Likely Deal Hunters https://t.co/3csjfHe132 $AMGN $GILD $MRK $PFE $PBYI $CARA $BMRN
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @JohnCendpts: GSK details PhIII success, preps global rollout for HIV combo as Gilead launches a counterattack
$GSK v. $GILD
https://t.c…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
RT @JohnCendpts: Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https:…
RT @JohnCendpts: GSK details PhIII success, preps global rollout for HIV combo as Gilead launches a counterattack
$GSK v. $GILD
https://t.c…
RT @adamfeuerstein: $GILD HIV ph2 data from CROI — bictegravir 97% “undetectable” at 24 wks and 48wks vs. $GSK dolutegravir 94% at 24 wks a…
Love these head-to-head match-ups. This is what benefits patients. $GSK vs. $GILD, both reporting stellar HIV data.
https://t.co/3cyTTvYPjA